Evidence map›Paper›PMID 40362222›Full record

ArticleInternational journal of molecular sciences2025

Highly Potent Neutralizing Nanobodies Acting Against Chikungunya Virus Infection via Inhibiting Multiple Stages of the Viral Life Cycle.

Liyuan Song, Guangcheng Fu, Jie Li, Zhengshan Chen, Ling Fu, Changming Yu, Li Qiang, Jiangfan Li, Ting Fang, Hongyu Yuan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liyuan SongLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Guangcheng FuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Jie LiCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Zhengshan ChenLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.ORCID 0000-0003-2869-1467
Ling FuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Changming YuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Li QiangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Jiangfan LiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.ORCID 0000-0001-6884-104X
Ting FangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Hongyu YuanLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Jianmin LiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.

Funding

National Natural Science Foundation of China 82202033
6 · The paper itself

Abstract

The Chikungunya virus (CHIKV) is a priority endemic pathogen identified by the World Health Organization and its infection induces an acute febrile illness in humans that is often associated with arthritis and musculoskeletal pain. Therefore, specific vaccines and treatments are urgently needed to prevent or treat Chikungunya disease. Here, we identify a series of CHIKV-specific neutralizing nanobodies (Nbs) from an alpaca which exhibit distinct binding modes compared to those previously reported. Two representative anti-CHIKV Nbs, N033-Fc and N053-Fc, demonstrated significant antiviral activity in

Indexed as

Antibodies, NeutralizingAntibodies, ViralChikungunya FeverChikungunya virusSingle-Domain AntibodiesAnimalsAntiviral AgentsHumansMiceMice, KnockoutReceptor, Interferon alpha-betaVero CellsVirus ReplicationAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsReceptor, Interferon alpha-betaSingle-Domain AntibodiesalpacaChikungunya virusnanobodyneutralizing antibodyp62-E1 heterodimer

Identifiers

PMID40362222
PMCPMC12071869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.